ThromboGenics shortlisted for two awards at the Scrip Awards 2009

ThromboGenics' Significant Achievements Over the Last Year are Recognised in Nominations

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a EUR500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of EUR50 million, an additional EUR450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fifth year running and the awards ceremony will take place on November 18, 2009 in London.

Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased to have been shortlisted for both the Biotech Company of the Year and Licensing Deal of the Year awards at this prestigious awards event. The nominations are a testament to the significant achievements and progress ThromboGenics has made over the last year. The Company is now in the best position to achieve its aim of becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines. We are very proud to be nominated amongst some of the most successful companies in the industry, and look forward to the results in November."